Other novel ADCs that may have therapeutic potential in HER2-mutant NSCLC include ARX788, which was tested in a phase I trial for the treatment of HER2-positive metastatic breast cancer (145), and MRG002, which was tested in a phase I dose escalation and expansion study in patients with HER2-positive solid tumors (146). This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.